Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for VERU.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -0.0519M
March 31, 2026 0.00
December 31, 2025 23.37M
September 30, 2025 0.00
June 30, 2025 0.00
March 31, 2025 0.00
December 31, 2024 -4.222M
September 30, 2024 0.00
June 30, 2024 0.0033M
March 31, 2024 -0.1503M
December 31, 2023 36.97M
September 30, 2023 2.118M
June 30, 2023 5.172M
March 31, 2023 2.268M
December 31, 2022 1.556M
September 30, 2022 0.6674M
June 30, 2022 0.154M
March 31, 2022 0.0434M
December 31, 2021 0.2044M
September 30, 2021 0.2323M
June 30, 2021 -0.5426M
March 31, 2021 108.35M
December 31, 2020 1.681M
September 30, 2020 -1.432M
June 30, 2020 9.517M
Date Value
March 31, 2020 0.8324M
December 31, 2019 0.4121M
September 30, 2019 -0.7554M
June 30, 2019 2.744M
March 31, 2019 -0.5859M
December 31, 2018 6.726M
September 30, 2018 1.00M
June 30, 2018 1.079M
March 31, 2018 10.00M
December 31, 2017 0.00
September 30, 2017 0.00
June 30, 2017 0.00
March 31, 2017 0.00
December 31, 2016 0.00
September 30, 2016 0.00
June 30, 2016 0.00
March 31, 2016 0.00
December 31, 2015 0.00
September 30, 2015 0.00
June 30, 2015 -0.0001M
March 31, 2015 -0.001M
December 31, 2014 -0.0052M
September 30, 2014 -0.5199M
June 30, 2014 -2.111M
March 31, 2014 -2.032M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
ANI Pharmaceuticals, Inc. -4.647M
Corcept Therapeutics, Inc. -2.037M
Johnson & Johnson -8.777B
Eli Lilly & Co. 8.426B
Lexicon Pharmaceuticals, Inc. -0.512M